FDA staff finds Intercept's liver drug effective as monotherapy

April 5, 2016 1:13 PM

14 0

The U.S. Food and Drug Administration's staff reviewers on Tuesday supported the use of Intercept Pharmaceuticals Inc's liver drug as a monotherapy in patients who did not respond to standard-of-care treatment.

The drug, obeticholic acid, is being reviewed for use in patients with primary biliary cirrhosis, a rare liver disease resulting from an autoimmune destruction of the bile ducts.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page